BPC
CDTX

Bryce Point Capital’s Cidara Therapeutics CDTX Stock Holding History

Bryce Point Capital’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$381K Buy
+3,977
New +$254K 0.46% 136

Other funds holding CDTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Bryce Point Capital's CDTX Position: Q3 2025 in Review

Bryce Point Capital opened a new position in Cidara Therapeutics (CDTX) in Q3 2025: 3,977 shares worth $381K. The stake represents 0.46% of the portfolio and ranks #136 among its holdings.

173 funds tracked by Wall St. Rank hold CDTX as of Q3 2025.

  • Bryce Point Capital held 3,977 shares of Cidara Therapeutics worth $381K as of Q3 2025.
  • Cidara Therapeutics was a new Bryce Point Capital position in Q3 2025.
  • Cidara Therapeutics made up 0.46% of Bryce Point Capital's portfolio in Q3 2025, its #136 holding.
  • 173 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q3 2025.

Based on Bryce Point Capital's 13F filing for Q3 2025, filed 6 Nov 2025.